Related medicinesLutropin alfa
Where it comes from
- Made in
- Gonadotroph cells of the anterior pituitary, which make FSH too
- Sent out by
- Fast GnRH pulses favour it; a surge at mid-cycle when oestrogen flips from inhibiting to stimulating; steady pulses in men
- Acts on
- Ovarian theca cells and the dominant follicle
- Corpus luteum
- Testicular Leydig cells
What it does
- Its mid-cycle surge ruptures the follicle and releases the egg, then turns the follicle into the corpus luteum
- Drives testosterone from the Leydig cells
- Rises after menopause and in testicular failure when the feedback is gone
In medicine
- Home ovulation tests detect the urinary LH surge
- Lutropin alfa, recombinant LH, is added to FSH in fertility treatment for women who lack it; hCG is usually used in its place to trigger ovulation 3
- Measured with FSH to sort out amenorrhoea, delayed puberty and hypogonadism: high in gonadal failure, low in pituitary or hypothalamic causes
Beyond the body’s own use
- Adding recombinant LH to FSH in IVF was reviewed across 14 trials and 2,612 women without a clear gain in pregnancy or live birth; the one group that may benefit is poor responders 1
- Kisspeptin, which sits upstream of GnRH, has been tried as a gentler trigger than hCG: in 60 women at high risk of ovarian hyperstimulation, kisspeptin-54 matured eggs in 95 per cent and none developed moderate or worse hyperstimulation 2
- Luteinizing hormone and chorionic gonadotropin are banned in sport in male athletes, because they raise testosterone from the testis; they are not prohibited for women 4
- A urinary test shows the surge and not the egg: a follicle can luteinise without rupturing, so a positive strip is evidence that LH rose and not proof that ovulation followed
Sources
- Mochtar et al., Recombinant luteinizing hormone for controlled ovarian hyperstimulation, Cochrane Database of Systematic Reviews 2007
- Abbara et al., Kisspeptin-54 to trigger oocyte maturation in women at high risk of OHSS, Journal of Clinical Endocrinology and Metabolism 2015
- EMA assessment report, Luveris
- World Anti-Doping Agency, The Prohibited List, section S2
This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.